 incidence sepsis expected increase rate 1.5% per year. Advances understanding sepsis syndrome enabled researchers identify new therapeutic targets design therapies existing mediators sepsis. Drotrecogin alfa (activated) first biological treatment serious sepsis approved Food Drug Administration 2001. also promising research results involving ethyl pyruvate, glycogen synthase kinase-3 inhibitors 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors. Here, review four compounds compound classes examples emerging pharmacological treatments severe sepsis describe current status sepsis research.